Hikichi Taiichi, Mori Fumihiko, Sasaki Mai, Takamiya Akira, Nakamura Masao, Shishido Naomi, Takeda Masumi, Horikawa Yoshitaka, Matsuoka Hidehito, Yoshida Akitoshi
Department of Ophthalmology, Asahikawa Medical College, Japan.
Curr Eye Res. 2002 Jan;24(1):1-5. doi: 10.1076/ceyr.24.1.1.5434.
We investigated the inhibitory effects of bucillamine on formation of laser-induced choroidal neovascularization (CNV) in a rat model.
Bucillamine administration (approximately 150 mg/kg/day) was started 1 week before photocoagulation and continued to the end of the study. Control groups received drinking water. Two weeks after photocoagulation, choroidal neovascularization development was evaluated using simultaneous fluorescein and indocyanine green angiography, and the maximal thickness of the lesions was measured histologically.
The incidence of CNV formation was 99.5 +/- 0.2% [mean +/- standard deviation (SD)] in control rats and 64.3 +/- 15.1% with bucillamine (P < 0.01). Histological study showed that the thickness of the CNV lesions was 23.4 +/- 6.5 microm (mean +/- SD) in the bucillamine-treated rats, which was significantly decreased compared to that in controls (60.8 +/- 9.2 microm) (P < 0.01).
Our results suggest that bucillamine may inhibit the development of laser-induced CNV in rats.
我们在大鼠模型中研究了布西拉明对激光诱导脉络膜新生血管形成(CNV)的抑制作用。
在光凝前1周开始给予布西拉明(约150毫克/千克/天),并持续至研究结束。对照组给予饮用水。光凝后2周,使用同步荧光素和吲哚菁绿血管造影评估脉络膜新生血管的发展,并通过组织学测量病变的最大厚度。
对照组大鼠CNV形成的发生率为99.5±0.2%[平均值±标准差(SD)],布西拉明组为64.3±15.1%(P<0.01)。组织学研究表明,布西拉明治疗的大鼠中CNV病变的厚度为23.4±6.5微米(平均值±SD),与对照组(60.8±9.2微米)相比显著降低(P<0.01)。
我们的结果表明布西拉明可能抑制大鼠激光诱导的CNV发展。